Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2018-07-19 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 3 pages 173.6KB
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for pictures and no substantive textual content. The true document length is only 411 characters, which is very short and does not contain any financial data, report content, or detailed information. It appears to be a very brief document or a placeholder with images omitted. Given the lack of any report content or detailed information, and the short length, this document is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other categories.
2018-07-19 English
Expansion of Genetic Risk Assessment Tests 2 pages 427.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 July 2018 from Genetic Technologies Limited. It announces the expansion of its range of genetic risk assessment tests and the upcoming launch of new breast cancer and colorectal cancer tests. The content is promotional and forward-looking, describing product development and future plans. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no merger or acquisition activity, and no legal proceedings. The document is a corporate announcement about product development and business updates, typical of a general regulatory announcement. It is relatively short (4034 characters) and does not contain or reference an attached report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2018-07-15 English
Change in substantial holding 4 pages 212.9KB
Regulatory Filings
2018-07-12 English
Lapse of Employee Share Options 2 pages 697.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 June 2018 regarding the lapse of employee share options. It provides details about the number of options lapsed, exercise prices, and outstanding options. The content is a specific update on employee share options, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about share options. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing, as it concerns employee options lapsing rather than new share issues or insider trades. The document length is under 5,000 characters, but it contains detailed information rather than just a notice of report availability, so it is not an RPA. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-06-28 English
Swisstec Heads of Agreement 3 pages 619.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 June 2018 regarding a Heads of Agreement between Genetic Technologies Limited and Swisstec Health Analytics Ltd to establish a joint venture company. The content focuses on the terms of the agreement, strategic collaboration, and future plans for the joint venture. There are no financial statements, audit information, or detailed financial performance data included. The document is a corporate announcement about a strategic partnership and joint venture formation, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through the joint venture equity arrangements. The document length is 7211 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2018-06-18 English
Binding Project Shivom Agreement 2 pages 445.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 7 June 2018 about a binding agreement between Genetic Technologies Limited and Project Shivom. It details the terms of a business collaboration, including funding and strategic goals. There are no financial statements, quarterly or annual results, or regulatory certifications. The content focuses on a capital or business development update related to a funding and partnership agreement. This fits the category of Capital/Financing Update (CAP). The document length is 6501 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2018-06-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.